Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act |
| |
| Authors: | Zaur Rzakhanov |
| |
| Institution: | Analysis Group, 111 Huntington Avenue, Tenth Floor, Boston, MA 02199, United States |
| |
| Abstract: | The U.S. Orphan Drug Act provides R&D incentives to drug-makers that go beyond statutory patent protection. The study explores the act's effect on financial returns to innovation and on the strategy of orphan drug development. Results indicate that the financial return to orphan drug development is positive. The findings suggest that when market size is small and cumulative innovation is an important phenomenon the policy that extends effective patent duration or subsidizes R&D activity improves incentives to innovate. |
| |
| Keywords: | Innovation R& D policy R& D strategy Orphan Drug Act |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
